Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 581 to 590 of 1447 total matches.
Two Long-Acting Injectable Antipsychotics for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Nov 09, 2015 (Issue 1481)
were then randomized to receive paliperidone
153
The Medical Letter ® Vol. 57 (1481) November 9, 2015 ...
The FDA has approved two new long-acting injectable
formulations of second-generation antipsychotics
for treatment of schizophrenia: aripiprazole lauroxil
(Aristada – Alkermes), which is given once every 4-6
weeks, and paliperidone palmitate (Invega Trinza –
Janssen), which is given once every 3 months.
Once-monthly injectable formulations of aripiprazole
(Abilify Maintena) and paliperidone palmitate (Invega
Sustenna) were approved earlier.
Cangrelor (Kengreal) - An IV Antiplatelet Drug for PCI
The Medical Letter on Drugs and Therapeutics • Oct 26, 2015 (Issue 1480)
hours (active metabolite)
146
The Medical Letter ® Vol. 57 (1480) October 26, 2015
death from any ...
The FDA has approved cangrelor (Kengreal – The
Medicines Company), an IV P2Y12 platelet inhibitor,
as an adjunct to percutaneous coronary intervention
(PCI) in patients who have not been pretreated with a
P2Y12 inhibitor and are not being given a glycoprotein
IIb/IIIa inhibitor.
Evolocumab (Repatha) - A Second PCSK9 Inhibitor to Lower LDL-Cholesterol
The Medical Letter on Drugs and Therapeutics • Oct 12, 2015 (Issue 1479)
were reported in ...
Evolocumab (Repatha – Amgen), a subcutaneously
injected PCSK9 inhibitor, has been approved by the
FDA as an adjunct to diet and maximally tolerated
statin therapy for adults with heterozygous familial
hypercholesterolemia (HeFH) or clinical atherosclerotic
cardiovascular disease who require additional
lowering of LDL-cholesterol (LDL-C). It was also
approved as an adjunct to diet and other LDL-lowering
therapies in patients with homozygous familial
hypercholesterolemia (HoFH) who require additional
lowering of LDL-C. Evolocumab is the second PCSK9
inhibitor to be approved in the...
Daclatasvir (Daklinza) for HCV Genotype 3 Infection
The Medical Letter on Drugs and Therapeutics • Oct 12, 2015 (Issue 1479)
of the drug were reduced when it was
143
The Medical Letter ® Vol. 57 (1479) October 12, 2015
taken ...
The FDA has approved daclatasvir (Daklinza – BMS),
an oral direct-acting antiviral drug, for use with
sofosbuvir (Sovaldi) for treatment of chronic hepatitis
C virus (HCV) genotype 3 infection. Daclatasvir is
the first drug approved for this indication that does
not require the addition of interferon or ribavirin. It is
approved in Japan and Europe in combination with
other drugs for treatment of HCV genotypes 1-4.
SGLT2 Inhibitors: New Reports
The Medical Letter on Drugs and Therapeutics • Oct 12, 2015 (Issue 1479)
(prior
myocardial infarction or stroke or angiographically
140
The Medical Letter ® Vol. 57 (1479 ...
The recent report of a reduction in cardiovascular
mortality in patients with type 2 diabetes treated with
the SGLT2 inhibitor empagliflozin (Jardiance) was
published soon after the FDA issued new warnings
about an increased risk of fractures with canagliflozin
(Invokana).
Eloctate for Hemophilia A
The Medical Letter on Drugs and Therapeutics • Oct 12, 2015 (Issue 1479)
quarter 2015.
5. The pre-surgery half-life is 16.7 hrs.
144
The Medical Letter ® Vol. 57 (1479) October ...
The FDA has approved Eloctate (Biogen), a recombinant
factor VIII Fc fusion protein with an extended half-life,
for use in adults and children with hemophilia
A. Eloctate is indicated for control and prevention of
bleeding episodes, perioperative management, and
routine prophylaxis to prevent or reduce the frequency
of bleeding episodes. It is the first antihemophilic factor
VIII Fc fusion protein to be approved for hemophilia A.
Flibanserin (Addyi) for Hypoactive Sexual Desire Disorder
The Medical Letter on Drugs and Therapeutics • Sep 28, 2015 (Issue 1478)
134
The Medical Letter ® Vol. 57 (1478) September 28, 2015
DRUG INTERACTIONS — Use of flibanserin ...
The FDA has approved flibanserin (Addyi – Sprout) for
treatment of premenopausal women with acquired,
generalized hypoactive sexual desire disorder
(HSDD) not caused by another medical or psychiatric
condition, the effects of another drug, or relationship
difficulties. Flibanserin is the first drug to be approved
for treatment of HSDD. It is not approved for use
in men or postmenopausal women. Previous FDA
reviews of flibanserin in 2010 and 2013 did not result
in approval.
Naloxegol (Movantik) for Opioid-Induced Constipation
The Medical Letter on Drugs and Therapeutics • Sep 28, 2015 (Issue 1478)
constipation who had been taking a stable dose of
136
The Medical Letter ® Vol. 57 (1478) September 28, 2015 ...
The FDA has approved naloxegol (Movantik –
AstraZeneca), a pegylated derivative of the opioid
antagonist naloxone, for oral treatment of opioid-induced
constipation in adults with chronic noncancer
pain. It is the only oral opioid antagonist approved for
this indication in the US.
Racemic Amphetamine Sulfate (Evekeo) for ADHD
The Medical Letter on Drugs and Therapeutics • Sep 28, 2015 (Issue 1478)
for neonatal withdrawal syndrome.
138
The Medical Letter ® Vol. 57 (1478) September 28, 2015
Table 2. Some ...
The FDA has approved racemic amphetamine sulfate
(Evekeo – Arbor) for oral treatment of attention-deficit/hyperactivity disorder (ADHD) in children ≥3 years old.
It was also approved for treatment of narcolepsy in
patients ≥6 years old and for short-term treatment of
obesity in patients ≥12 years old.
ReShape and Orbera - Two Gastric Balloon Devices for Weight Loss
The Medical Letter on Drugs and Therapeutics • Aug 31, 2015 (Issue 1476)
The Medical Letter ® Vol. 57 (1476) August 31, 2015
a serotonin-norepinephrine reuptake inhibitor (SNRI ...
The FDA has approved the ReShape Integrated Dual
Balloon System (ReShape Medical) and the Orbera
Intragastric Balloon System (Apollo Endosurgery) for
up to 6 months of use in adults with a BMI of 30-40
who have not been able to maintain weight loss with
a weight loss program and, for ReShape, who have at
least one obesity-related comorbidity. Both devices
have been available in the European Union and
elsewhere for years (20 years for Orbera). Three other
devices, the LAP-Band, the Realize adjustable gastric band, and the Maestro Rechargeable System, are FDA-approved
for long-term...